HealthCuring Blindness Through Gene Therapy Might Soon Be Allowed By The FDA Patients whose blindness is a result of an RPE65 gene might soon consider Luxturna, a form of gene therapy that improves vision. Its approval will soon be deliberated by the U.S. Food and Drug Administration.by Carl Velasco
HealthScientific Panel Seeks Harsher Strategy, Total Policy Overhaul To Solve Opioid Problemby Katrina Pascual
HealthNovartis CAR-T Cancer Therapy For Leukemia Gets Landmark Recommendation From FDA Panelby Alyssa Navarro